Nimotuzumab Plus Gemcitabine-based Adjuvant Chemotherapy for Resectable Pancreatic Cancer: A Retrospective Observational Study
By adding nimotuzumab to existing gemcitabine-based AC regimens, RPC patients would show a survival benefit trend with a satisfactory safety profile.
Authors
- Fanlu Li
- Siyi Zou (ORCID: https://orcid.org/0000-0002-0762-4110)
- Chenlei Wen (ORCID: https://orcid.org/0000-0003-3458-5409)
- Qiang Tian (ORCID: https://orcid.org/0000-0002-1924-6217)
- Lingxi Jiang (ORCID: https://orcid.org/0000-0002-8070-5275)
- Chenghong Peng
- Baiyong Shen
- Xiaxing Deng
- Qian Zhan (ORCID: https://orcid.org/0000-0002-2842-6156)
- Hao Chen
Institutions
- Shanghai Jiao Tong University (CN)
- Ruijin Hospital (CN)
- Shanghai Institute of Hematology (CN)
Publication Details
- Journal
- Pancreas
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1097/mpa.0000000000002511
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00